Rank #1: PL Voices: Vitamin D Controversy
This one took place on February 17, 2016 and is led by our Editor, Sherri Boehringer, PharmD, BCPS. You’ll hear the voices of preventive medicine expert JoAnn E. Manson, MD, DrPH, FAHA, Harvard Medical School, Massachusetts; and guest panelist Barbara P. Yawn, MD, MSc, MPSH, FAAFP, University of Minnesota. You can read our brief, to-the-point Recommendation and dive into the evidence-based details if you wish.
To learn more, visit pharmacistsletter.com.
Apr 07 2016
Rank #2: PL Live: Improving Metformin Tolerability
We know metformin is our go-to med for type 2s due to well-established safety and efficacy...possible CV benefits...and low cost. Plus it seems safer than previously thought in stable kidney disease.
But GI side effects can lead to poor adherence...impacting glucose control AND Star Ratings.
Be ready to help patients give metformin a fair trial.
Set the stage for what to expect. Explain that GI problems such as diarrhea are usually short-lived...especially with a slow titration.
Recommend starting with 500 mg daily...or even just 250 mg daily for some. Suggest titrating by 250 to 500 mg every 1 or 2 weeks as tolerated.
Advise backing off to the previous dose if GI side effects are a problem...and trying another dose increase after about 2 weeks.
It's okay if it takes weeks or months to reach the target dose of 2 g/day. And don't feel compelled to aim for doses higher than this...they don't lower glucose much more, but may increase GI side effects.
Consider REtitrating if a patient stops metformin for even a couple of days...especially if GI problems occurred when it was started.
Avoid administration pitfalls. For example, suggest taking metformin during or right after a large meal to improve tolerability.
If needed, suggest giving the ER dose BID instead of once daily.
Suggest switching metformin products if needed. Extended-release forms often need less frequent dosing...and seem to cause fewer GI side effects. Plus, some of the ER generics now cost as little as $10/month.
Discourage Glumetza. It's the only metformin ER product without a generic, and it costs about $6700 per month...and that's not a typo. Plus, there's no good evidence any ER product is better tolerated than another.
Also consider a different generic if pill odor is a problem. Odor varies between products...and ER tabs may not smell as bad.
Apr 07 2016
Rank #3: PL Live: Safe Use of Dietary Supplements
People often think of supplements as "safe." But new evidence shows that supplement adverse events lead to about 23,000 ED visits every year.
Over half of these visits are for CV issues, such as chest pain or palpitations, in younger people using weight loss or energy supplements.
That's because these often contain stimulants or caffeine sources such as guarana, yerba mate, kola nut, bitter orange, etc.
Use this as an opportunity to help patients use a common sense approach with supplements. Point out that "natural" doesn't mean "safe."
Give examples of plants that are well known to be toxic...poison ivy, deadly nightshade, hemlock, jimson weed, oleander, foxglove, etc.
Explain that FDA doesn't regulate supplements like Rx drugs. It doesn't require testing for efficacy and safety...or require proof of quality before marketing.
Plus, supplements aren't required to have warnings about side effects or drug interactions.
But this doesn't mean they don't exist.
For example, yohimbine can cause arrhythmias...and American ginseng can significantly decrease warfarin efficacy and INR.
If people want to use a supplement, suggest choosing one with the USP Verified Mark when possible.
Pick your battles...and know when to step in. For example, CoQ10 is unlikely to harm when used for statin muscle pain...but St. John's wort shouldn't be used with oral contraceptives because it can reduce efficacy.
Use our Natural Medicines to check for interactions, efficacy, etc...and use our Natural MedWatch to report supplement side effects. PL Detail-Document #311209
Apr 07 2016
Rank #4: Article: Reducing Readmissions for Heart Failure Patients
But early follow-up from you...their pharmacist...can help.
For example, talking with patients within 2 days of discharge PLUS an office visit within 7 days prevents one ED visit for every 9 heart failure patients...and one readmission for every 52 patients.
Expect to see more hospitals, prescribers, and payers looking to work with YOU to help reduce readmissions.
Your expertise can improve care...and save money. Think of your role managing heart failure as similar to managing anticoag patients. There'll be professional and financial opportunity in it.
Offer comprehensive med reviews to identify and resolve problems.
Recommend an ACEI or ARB plus an "evidence-based" beta-blocker...bisoprolol, carvedilol, or metoprolol SUCCINATE...for systolic heart failure. Suggest adding an aldosterone antagonist if symptoms persist.
Recommend trying to titrate to target doses that improve survival, such as lisinopril 20 to 40 mg/day or metoprolol succinate 200 mg/day.
Consider suggesting Entresto (sacubitril/valsartan) instead of the ACEI or ARB if hospitalization occurs despite use of target doses. But be aware of hypotension, and avoid Entresto when systolic BP < 100 mmHg.
Educate patients about self-management...and when to get help. Include caregivers...they are crucially important to success in many cases.
Consider using a heart failure questionnaire from our PL Detail-Document to identify red flags BEFORE patients get worse. For example, advise patients to report if weight changes by more than a few pounds.
Emphasize adherence with meds, limiting fluids, diet, etc. For example, help patients understand how taking their ACEI or ARB improves their outcomes. Plus this also impacts Star Ratings.
Suggest pillboxes or consider offering med sync to boost adherence. Use our PL Conversation Starter to guide your discussions.
Communicate with colleagues if you find problems with med lists or identify adherence issues...to prevent gaps in therapy.
Apr 07 2016
Rank #5: Article: First Time Generics for 2016
But don't expect drastic price drops initially...the first generic usually has 180-day exclusivity before other generics come out.
Prepare patients for these switches. Explain these are best-guess release dates...they can change due to legal maneuverings, etc.
OxyContin (oxycodone ER)...available now. But advise patients generics are only out for the 10, 20, 40, and 80 mg tabs so far.
Gleevec (imatinib)...February. This could be a game changer for certain leukemias...since the brand costs about $10,000/month.
Crestor (rosuvastatin)...May. This is big...it's the only high-intensity statin besides atorvastatin. Consider rosuvastatin if interactions or muscle problems are an issue with atorvastatin.
Nuvigil (armodafinil)...June. Explain armodafinil may last longer than modafinil...but there's no proof it's better or safer.
Suggest either option for shift workers if nondrug treatments (sleep hygiene, etc) and caffeine aren't enough.
Benicar (olmesartan)...October. It will join a handful of other generic ARBs. Pick one based on payer preference.
ProAir HFA (albuterol)...December. Explain this generic will NOT be equivalent to Ventolin HFA, Proventil HFA, or ProAir RespiClick. Encourage prescribers to write "albuterol HFA" to give you flexibility.
Zetia (ezetimibe)...December or early 2017. Suggest saving ezetimibe as an add-on for high-risk patients who can't tolerate a high-intensity statin.
For patients on Vytorin, consider suggesting generic ezetimibe plus a generic statin instead...at least until Vytorin goes generic.
Also look for Basaglar in late 2016. It's a new BRAND of insulin glargine that will be similar to Lantus...NOT a generic or biosimilar.
Apr 07 2016